US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
- Mechanism
- Dihydrofolate reductase inhibitor
pharma · Colorectal Cancer Screening · Screening for Colon Cancer · MRKR
ME Therapeutics
Marker Therapeutics
ME Therapeutics drug portfolio — 10 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Vancouver, British Columbia, CA HQ
2018 Founded
4 Employees
Public company Type
MRKR · NYSE Ticker
Company details
- Status
- Public
- HQ
- Vancouver, British Columbia, CA
- Founded
- 2018
- Employees
- 4
- Programs
- 13
- Drugs
- 10
- Patents
- 27
ME Therapeutics pipeline
Portfolio lens on 10 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
ME Therapeutics drug portfolio — 10 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Mechanism: Surfactant agent.
- Mechanism
- Surfactant agent
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to ME Therapeutics in public FDA and regional records.
-
Development asset linked to ME Therapeutics in public FDA and regional records.
-
Development asset linked to ME Therapeutics in public FDA and regional records. Molecular target: Granulocyte colony-stimulating factor receptor.
- Target
- Granulocyte colony-stimulating factor receptor
- Mechanism
- Granulocyte colony stimulating factor receptor agonist
-
Development asset linked to ME Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
Development asset linked to ME Therapeutics in public FDA and regional records.